OneSource Specialty Pharma has entered into a strategic manufacturing partnership with Formycon AG (Formycon), an independent biosimilar developer headquartered in Munich, for biosimilars. Under the partnership, the company will serve as a strategic manufacturing partner for Formycon and provide integrated Drug Substance (DS) and Drug Product (DP) manufacturing capabilities from its state-of-the-art biologics’ facility in Bangalore. The collaboration brings together Formycon’s Biosimilar development excellence with the company’s end-to-end biologics manufacturing expertise to support Formycon's biosimilar programs for global markets.
The partnership reflects the shared commitment of both companies to advancing global access to biosimilars through reliable, high-quality, and scalable manufacturing. Achieving this requires not only scientific excellence but also a sustainable, cost-effective manufacturing model - that the company is specifically positioned to deliver.
Formycon brings a strong track record in biosimilar development and commercialization, supported by an established portfolio and a robust pipeline. The company complements this with an integrated biologics platform spanning cell line development through commercial fill-finish, five manufacturing facilities approved by leading global regulatory authorities, including the US FDA and EMA, and extensive expertise across biologics, sterile injectables, and drug-device combinations.
OneSource Specialty Pharma is a multimodal specialty pharma CDMO with end-to-end capabilities across technology platforms and therapeutic modalities.
